These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36181379)

  • 21. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
    Painter WP; Holman W; Bush JA; Almazedi F; Malik H; Eraut NCJE; Morin MJ; Szewczyk LJ; Painter GR
    Antimicrob Agents Chemother; 2021 May; 65(5):. PubMed ID: 33649113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.
    Hadj Hassine I; Ben M'hadheb M; Menéndez-Arias L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes.
    Chawla A; Birger R; Wan H; Cao Y; Maas BM; Paschke A; De Anda C; Rizk ML; Stone JA
    Clin Pharmacol Ther; 2023 Jun; 113(6):1337-1345. PubMed ID: 37017631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N4-hydroxycytidine: a mutagen specific for AT to GC transitions.
    Janion C; Glickman BW
    Mutat Res; 1980 Aug; 72(1):43-7. PubMed ID: 6160396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19.
    Jena NR
    Phys Chem Chem Phys; 2020 Dec; 22(48):28115-28122. PubMed ID: 33290476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficiency and extent of mutagenic activity of some new mutagens of base-analogue type.
    Janion C
    Mutat Res; 1978 Jan; 56(3):225-34. PubMed ID: 342940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of assays for the quantification of β-D-N
    Parsons TL; Kryszak LA; Marzinke MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122921. PubMed ID: 34555541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N4-aminocytidine, a nucleoside analog that has an exceptionally high mutagenic activity.
    Negishi K; Harada C; Ohara Y; Oohara K; Nitta N; Hayatsu H
    Nucleic Acids Res; 1983 Aug; 11(15):5223-33. PubMed ID: 6224136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molnupiravir for the treatment of COVID-19.
    Santani BG; LeBlanc BW; Thakare RP
    Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2.
    Celik I; Tallei TE
    J Cell Biochem; 2022 Apr; 123(4):807-818. PubMed ID: 35132671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β-d-
    Urakova N; Kuznetsova V; Crossman DK; Sokratian A; Guthrie DB; Kolykhalov AA; Lockwood MA; Natchus MG; Crowley MR; Painter GR; Frolova EI; Frolov I
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29167335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
    Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
    Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutagenesis of Escherichia coli: a method for determining mutagenic specificity by analysis of tRNA suppressors.
    Sledziewska-Gójska E; Grzesiuk E; Plachta A; Janion C
    Mutagenesis; 1992 Jan; 7(1):41-6. PubMed ID: 1378922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites.
    Miller SR; McGrath ME; Zorn KM; Ekins S; Wright SH; Cherrington NJ
    Mol Pharmacol; 2021 Dec; 100(6):548-557. PubMed ID: 34503974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic.
    Harfoot R; Lawley B; Hernández LC; Kuang J; Grant J; Treece JM; LeQueux S; Day R; Jack S; Stanton JL; Bostina M; Ussher JE; Quiñones-Mateu ME
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.